Zinplava® (bezlotoxumab)

Last Review Date: July 15, 2019
Number: MG.MM.PH.184

Medical Guideline Disclaimer

All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and website links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Ziplava is a human monoclonal antibody. It binds to Clostridium difficile toxin B, which prevents toxin B from binding to and affecting mammalian cells. It is approved to reduce recurrence of CDI in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence. Zinplava is not indicated for the treatment of CDI. Zinplava is not an antibacterial drug and should only be used in conjunction with antibacterial drug treatment of CDI.

Length of Authorization

Coverage will be provided for 1 dose.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:

- 10 mg/kg for 1 dose

I. INITIAL APPROVAL CRITERIA

Zinplava may be considered medically necessary if the below condition is met AND use is consistent with the medical necessity criteria that follows:

1. Clostridium difficile infection (CDI), recurrent
   a. Patient is 18 years of age or older; AND
   b. Member has a confirmed diagnosis of Clostridium difficile infection (CDI) with documentation of the following: diarrhea (passage of 3 or more loose bowel movements in 24 or fewer hours) and a positive stool test for toxigenic C. difficile from a stool sample collected no more than 7 days prior; AND
   c. Member is at high risk of CDI recurrence, defined as any of the following:
      i. Age greater than or equal to 65 years; OR

OR
ii. Long term use of systemic antibacterial drugs (excluding standard of care antibiotics); OR

iii. History of 1 or more prior episodes of CDI within the previous 6 months; OR

iv. Immunocompromised (defined as having an active hematologic malignancy, using an antineoplastic or immunomodulating agent, using corticosteroids, having received a prior solid organ transplant, being asplenic, being neutropenic/pancytopenic, or having AIDS/immunodeficient condition); OR

v. Clinically severe CDI (as defined by a Zar score of greater than or equal to 2); OR

vi. Hypervirulent strain (ribotypes 027, 078 or 244); AND

d. Bezlotoxumab will be given in conjunction with standard of care antibiotics (Infusion will be given during the antibiotic treatment course)

Limitations/Exclusions

1) Zinplava should be used only in conjunction with antibacterial drug treatment of CDI.

2) The use of Zinplava is considered investigational when the above criteria are not met, and for all other conditions, including but not limited to first-line therapy.

II. RENEWAL CRITERIA

• Repeat administration of Zinplava is considered experimental and investigational.

Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clostridium difficile infection (CDI), recurrent</td>
<td>10 mg/kg administered as an intravenous infusion over 60 minutes as a single dose.</td>
</tr>
</tbody>
</table>

Applicable Procedure Codes

| J0565 | Injection, bezlotoxumab, 10 mg, 1 billable unit = 10 mg |

Applicable NDCs

| 00006-3025-00 | Ziplava single use vial; 25 mg/1 ml solution |

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A04.71-A04.72</td>
<td>Enterocolitis due to Clostridium difficile</td>
</tr>
</tbody>
</table>

References